Adverse Event

Terminology Distinctions

Term	Definition
Adverse Event (AE)	Any bad outcome while on treatment (may or may not be drug-related)
Adverse Drug Reaction (ADR)	Event where drug causation is suspected or established
Side Effect	Expected pharmacological effect (can be desired or undesired)
Serious Adverse Event (SAE)	AE that is life-threatening, requires hospitalization, or causes disability
Unexpected AE	Not listed in product labeling or different in severity

Adverse Event Classification

By Severity Grade

Grade	Description	Example
Grade 1 (Mild)	Noticeable but no interference with activities	Mild nausea
Grade 2 (Moderate)	Interferes with some activities	Nausea limiting food intake
Grade 3 (Severe)	Prevents normal activities	Unable to work due to nausea
Grade 4 (Life-threatening)	Immediate risk of death	Severe dehydration requiring ICU
Grade 5 (Death)	Fatal outcome	Death from complication

By Causality Assessment

Category	Definition	Criteria
Definite	Clearly drug-related	Temporal relationship, improves when stopped, recurs on rechallenge
Probable	Likely drug-related	Reasonable temporal relationship, unlikely other cause
Possible	May be drug-related	Could be drug or could be other factors
Unlikely	Probably not drug-related	Weak temporal relationship, alternative explanation
Unrelated	Not drug-related	Clear alternative cause identified

Common GLP-1 Agonist Adverse Events

Gastrointestinal Events (Most Frequent)

Event	Frequency	Typical Course
Nausea	20-44%	Usually improves over 4-8 weeks
Diarrhea	10-30%	Often transient, first weeks
Vomiting	10-25%	Usually early in treatment
Constipation	10-24%	May persist, manageable
Abdominal pain	5-20%	Variable duration
Dyspepsia	5-15%	May improve with dose stabilization

Other Notable Events

Event	Frequency	Clinical Notes
Injection site reactions	5-10%	Usually mild, local
Fatigue	5-15%	Often improves over time
Headache	5-15%	Variable, usually mild
Dizziness	3-10%	May relate to food intake changes
Hypoglycemia	Rare alone	Higher risk with insulin/sulfonylureas

Serious Adverse Events (SAEs)

Regulatory Definition

An SAE is any adverse event that:

• Results in death
• Is life-threatening
• Requires inpatient hospitalization
• Results in persistent disability/incapacity
• Causes congenital anomaly/birth defect
• Is otherwise medically significant

GLP-1 Agonist SAEs Under Surveillance

Condition	Evidence Status	Monitoring Recommendation
Pancreatitis	Reported, rare	Monitor for severe abdominal pain
Gallbladder disease	Clinical trial signal	Monitor for biliary symptoms
Thyroid tumors	Animal studies	Patient/family history screening
Acute kidney injury	Post-marketing reports	Monitor renal function
Diabetic retinopathy	Rapid glucose change	Eye exams in diabetic patients

Adverse Event Reporting

During Clinical Trials

Process Step	Responsible Party
Detection	Patient, investigator
Documentation	Investigator
Assessment	Investigator (causality, severity)
Reporting	To sponsor (immediate for SAEs)
Analysis	Sponsor, safety committee

Post-Marketing Surveillance

System	Description
FAERS	FDA Adverse Event Reporting System
MedWatch	FDA’s safety reporting portal
Healthcare providers	Should report serious/unexpected events
Patients	Can report directly to FDA
Manufacturers	Required to report and investigate

Reading Adverse Event Data

Key Metrics

Metric	Meaning
Incidence	Percentage of patients experiencing event
NNH	Number needed to harm (patients treated per one event)
Relative risk	Comparison to placebo or comparator
Attributable risk	Excess events caused by drug

Interpretation Example

“Nausea: 40% on drug vs 10% on placebo”

• Absolute difference: 30%
• Relative risk: 4x higher on drug
• NNH: ~3-4 (one extra nausea case per 3-4 patients treated)
• 60% on drug did NOT experience nausea

Managing Adverse Events

General Strategies

Strategy	Application
Slow titration	Start low, increase gradually
Dose reduction	If events intolerable at higher dose
Symptomatic treatment	OTC remedies when appropriate
Watchful waiting	Many events improve with time
Discontinuation	If severe, persistent, or dangerous

GI Event Management

Approach	Specific Recommendations
Dietary	Smaller meals, avoid fatty foods
Timing	Take with or without food per tolerance
Hydration	Maintain fluid intake
Anti-nausea	Ginger, OTC antiemetics if needed
Fiber	For constipation management
Communication	Report persistent or severe symptoms

Frequently Asked Questions

Does experiencing side effects mean the drug is working?

Not necessarily. Adverse events indicate drug activity in the body but don’t correlate with efficacy. Some patients achieve excellent results with minimal side effects; others have significant side effects without optimal response.

Should I stop my medication if I have side effects?

It depends on severity and type. Many GLP-1 side effects (especially GI) improve over weeks and can be managed. Severe or concerning symptoms warrant medical evaluation. Never stop suddenly without discussing with your healthcare provider.

Are clinical trial adverse events representative of real-world use?

Somewhat. Trials have controlled conditions and selected populations. Real-world use involves more diverse patients, comorbidities, and concomitant medications. Post-marketing surveillance captures real-world patterns that may differ from trials.

How do I report an adverse event?

Contact your healthcare provider for medical evaluation. You or your provider can report to FDA through MedWatch (fda.gov/medwatch) or by calling 1-800-FDA-1088. Manufacturers also have reporting mechanisms on their websites.